Bortezomib vs no bortezomib: Progression‐free survival (PSF)
Bortezomib probably leads to lower progression‐Free Survival ‐ Bortezomib versus no bortezomib (same… compared with no bortezomib (moderate certainty).
What each review found
Include earlier review versions| Finding | Effect | Studies | GRADE certainty |
|---|---|---|---|
Bortezomib vs no bortezomib Progression‐Free Survival ‐ Bortezomib versus no bortezomib (same background therapy) · All patients with a diagnosis of multiple myeloma Bortezomib probably leads to lower progression‐Free Survival ‐ Bortezomib versus no bortezomib (same… compared with no bortezomib (moderate certainty). Bortezomib for the treatment of multiple myeloma (2016) · Cochrane Headline outcomes only | Odds Ratio 0.65 [0.57, 0.74] | 5 studies · 1855 participants | Moderate |
Findings are shown side by side, never pooled across reviews.
The reviews
| Review | Searched up to | Included studies | AMSTAR 2 |
|---|---|---|---|
| Bortezomib for the treatment of multiple myeloma 2016 · Cochrane Headline outcomes only | Not reported | list not extracted yet | Not assessed |
Studies behind the findings
None of these reviews ties its included studies to this outcome in the data here. Cochrane reviews and reviews with headline outcomes only do not list their studies yet.
How reviews are matched to this question
Reviews word the same question differently. Four decision models (TypeSafe's Jev, Liquid AI's d1-ultra, SubQ Snap and Baseten's Elephant) judged each wording of the population, intervention, comparator and outcome against the others; two wordings count as the same when at least three of them agree and none clearly disagrees, and findings count as this question only when all four elements match. Timing, setting and subgroup never split a question: they are shown on each finding.